Photo of Lowell E. Schnipper,  MD

Lowell E. Schnipper, MD

Beth Israel Deaconess Medical Center

Beth Israel Deaconess Medical Center
Phone: (617) 667-2176
Fax: (617) 667-3915

Lowell E. Schnipper, MD

Beth Israel Deaconess Medical Center


  • Theodore W. and Evelyn G. Berenson Professor, Medicine, Harvard Medical School
  • Chief, Hematology/Oncology, Beth Israel Deaconess Medical Center
  • Clinical Director, Beth Israel Deaconess Medical Center Cancer Center, Beth Israel Deaconess Medical Center



  • Institutional Representative for BIDMC, Membership Committee
  • Member, Clinical Science Coordinating Committee
  • Member, Center Scientific Council
  • Chair, Membership Committee
  • Associate Director, Membership, Executive Committee
  • Deputy Associate Director, Clinical Science, Executive Committee

Research Abstract

Our long term interest is in 2 general areas:

1. Genomic instability: we have developed a model system with which to identify the emergence of DNA rearrangements that follow exposure to a specific stimulus, e.g., exposure to a viral oncoprotein such as the AdE1A, or polyoma middle T antigens. We have established that these oncoproteins are necessary but not sufficient for induction of DNA rearrangements. Recent work has focused on other factors that mediate the induction of genetic rearrangements. Differential display analyses demonstrated the presence of several unique cDNAs the expression of which is upregulated, which are homologues of known helicases and appear to have an important role in generating a rearrangement event.

2. Another interest is the basis of resistance and sensitivity to inhibitors of topoisomerase II. We have cloned the hamster cDNA for top II and demonstrated the point mutation associated with drug resistance, and have cloned the promoter of the human topII alpha gene. Using conditional mutants we have demonstrated that sensitivity and resistance to inhibitors of top II are correlated with expression of this enzyme, and that the latter is inversely correlated with resistance to alkylating agents.

3. A distinct focus of our research has been a longstanding series of clinical investigations that are evaluating the efficacy of high dose chemotherapy and autologous stem cell reinfusion as a novel therapy for patients with advance solid tumors, e.g., breast cancer, testis cancer, small cell carcinoma of the lung, recurrent malignant lymphoma (HD and NHL). The studies undertaken have been a product of a collaboration by investigators at the BIDMC and the DFCI, and have been performed by the Solid Tumor Autologous Program (STAMP). The thrust of the clinical studies being performed by this group is twofold: enhancing the efficacy of high dose therapy by identifying new agents to be incorporated into this experimental therapeutic context, and the studies designed to understand minimal residual disease (MRD) and develop novel approaches to its treatment -- specifically employing vaccine and other inmmunologic strategies.


Powered by Harvard Catalyst
  • Schnipper LE, Davidson NE, Wollins DS, Tyne C, Blayney DW, Blum D, Dicker AP, Ganz PA, Hoverman JR, Langdon R, Lyman GH, Meropol NJ, Mulvey T, Newcomer L, Peppercorn J, Polite B, Raghavan D, Rossi G, Saltz L, Schrag D, Smith TJ, Yu PP, Hudis CA, Schilsky RL. American Society of Clinical Oncology Statement: A Conceptual Framework to Assess the Value of Cancer Treatment Options. J Clin Oncol 2015. PubMed
  • Schnipper LE, Meropol NJ. Payment for cancer care: time for a new prescription. J Clin Oncol 2014; 32:4027-8. PubMed
  • Schnipper LE. Quality oncology practice initiative: an approach to solving the value equation. J Oncol Pract 2014; 10:219-20. PubMed
  • Ellis LM, Bernstein DS, Voest EE, Berlin JD, Sargent D, Cortazar P, Garrett-Mayer E, Herbst RS, Lilenbaum RC, Sima C, Venook AP, Gonen M, Schilsky RL, Meropol NJ, Schnipper LE. American society of clinical oncology perspective: raising the bar for clinical trials by defining clinically meaningful outcomes. J Clin Oncol 2014; 32:1277-80. PubMed
  • Shih YC, Ganz PA, Aberle D, Abernethy A, Bekelman J, Brawley O, Goodwin JS, Hu JC, Schrag D, Temel JS, Schnipper L. Delivering high-quality and affordable care throughout the cancer care continuum. J Clin Oncol 2013; 31:4151-7. PubMed
  • Schnipper LE. The rising cost of cancer care: physicians take charge. J Oncol Pract 2012; 8:e87-8. PubMed
  • Peppercorn JM, Smith TJ, Helft PR, Debono DJ, Berry SR, Wollins DS, Hayes DM, Von Roenn JH, Schnipper LE, . American society of clinical oncology statement: toward individualized care for patients with advanced cancer. J Clin Oncol 2011; 29:755-60. PubMed
  • LoRusso PM, Schnipper LE, Stewart DJ, Boerner SA, Averbuch SD, Wolf W. Translating clinical trials into meaningful outcomes. Clin Cancer Res 2010; 16:5951-5. PubMed
  • Schnipper LE, Meropol NJ, Brock DW. Value and cancer care: toward an equitable future. Clin Cancer Res 2010; 16:6004-8. PubMed
  • Meropol NJ, Schrag D, Smith TJ, Mulvey TM, Langdon RM, Blum D, Ubel PA, Schnipper LE, . American Society of Clinical Oncology guidance statement: the cost of cancer care. J Clin Oncol 2009; 27:3868-74. PubMed
  • Schnipper LE. Update in oncology. Ann Intern Med 2007; 147:775-82. PubMed
  • Miksad RA, Schnipper L, Goldstein M. Does a statistically significant survival benefit of erlotinib plus gemcitabine for advanced pancreatic cancer translate into clinical significance and value? J Clin Oncol 2007; 25:4506-7; author reply 4508. PubMed
  • Pentz RD, Joffe S, Emanuel EJ, Schnipper LE, Haskell CM, Tannock IF. ASCO core values. J Clin Oncol 2006; 24:5780-2. PubMed
  • Li FP, Fletcher JA, Heinrich MC, Garber JE, Sallan SE, Curiel-Lewandrowski C, Duensing A, van de Rijn M, Schnipper LE, Demetri GD. Familial gastrointestinal stromal tumor syndrome: phenotypic and molecular features in a kindred. J Clin Oncol 2005; 23:2735-43. PubMed
  • Merchan JR, Chan B, Kale S, Schnipper LE, Sukhatme VP. In vitro and in vivo induction of antiangiogenic activity by plasminogen activators and captopril. J Natl Cancer Inst 2003; 95:388-99. PubMed
  • Gilligan TD, Carrington MA, Sellers TP, Casal L, Schnipper LE, Li FP. Cancer survivorship issues for minority and underserved populations. Cancer Epidemiol Biomarkers Prev 2003; 12:284s-286s. PubMed
  • Eder JP, Supko JG, Clark JW, Puchalski TA, Garcia-Carbonero R, Ryan DP, Shulman LN, Proper J, Kirvan M, Rattner B, Connors S, Keogan MT, Janicek MJ, Fogler WE, Schnipper L, Kinchla N, Sidor C, Phillips E, Folkman J, Kufe DW. Phase I clinical trial of recombinant human endostatin administered as a short intravenous infusion repeated daily. J Clin Oncol 2002; 20:3772-84. PubMed
  • Vonderheide RH, Schultze JL, Anderson KS, Maecker B, Butler MO, Xia Z, Kuroda MJ, von Bergwelt-Baildon MS, Bedor MM, Hoar KM, Schnipper DR, Brooks MW, Letvin NL, Stephans KF, Wucherpfennig KW, Hahn WC, Nadler LM. Equivalent induction of telomerase-specific cytotoxic T lymphocytes from tumor-bearing patients and healthy individuals. Cancer Res 2001; 61:8366-70. PubMed
  • Schnipper LE, Strom TB. A magic bullet for cancer--how near and how far? N Engl J Med 2001; 345:283-4. PubMed
  • Hilden JM, Emanuel EJ, Fairclough DL, Link MP, Foley KM, Clarridge BC, Schnipper LE, Mayer RJ. Attitudes and practices among pediatric oncologists regarding end-of-life care: results of the 1998 American Society of Clinical Oncology survey. J Clin Oncol 2001; 19:205-12. PubMed
  • Elias A, Ibrahim J, Skarin AT, Wheeler C, McCauley M, Ayash L, Richardson P, Schnipper L, Antman KH, Frei E. Dose-intensive therapy for limited-stage small-cell lung cancer: long-term outcome. J Clin Oncol 1999; 17:1175. PubMed
  • Chan CY, Molrine DC, Antin JH, Wheeler C, Guinan EC, Weinstein HJ, Phillips NR, McGarigle C, Harvey S, Schnipper C, Ambrosino DM. Antibody responses to tetanus toxoid and Haemophilus influenzae type b conjugate vaccines following autologous peripheral blood stem cell transplantation (PBSCT). Bone Marrow Transplant 1997; 20:33-8. PubMed
  • Wheeler C, Eickhoff C, Elias A, Ibrahim J, Ayash L, McCauley M, Mauch P, Schwartz G, Eder JP, Mazanet R, Ferrara J, Rimm IJ, Guinan E, Bierer B, Gilliland G, Churchill WH, Ault K, Parsons S, Antman K, Schnipper L, Tepler I, Gaynes L, Frei E 3rd, Kadin M, Antin J. High-dose cyclophosphamide, carmustine, and etoposide with autologous transplantation in Hodgkin's disease: a prognostic model for treatment outcomes. Biol Blood Marrow Transplant 1997; 3:98-106. PubMed
  • Drews RE, Kolker MT, Sachar DS, Moran CP, Schnipper LE. Passage to nonselective media transiently alters growth of mycophenolic acid-resistant mammalian cells expressing the escherichia coli xanthine-guanine phosphoribosyltransferase gene: implications for sequential selection strategies. Anal Biochem 1996; 235:215-26. PubMed
  • Eder JP, Chan VT, Ng SW, Rizvi NA, Zacharoulis S, Teicher BA, Schnipper LE. DNA topoisomerase II alpha expression is associated with alkylating agent resistance. Cancer Res 1995; 55:6109-16. PubMed
  • Ng SW, Eder JP, Schnipper LE, Chan VT. Molecular cloning and characterization of the promoter for the Chinese hamster DNA topoisomerase II alpha gene. J Biol Chem 1995; 270:25850-8. PubMed
  • Tepler I, Schwartz G, Parker K, Charette J, Kadin ME, Woodworth TG, Schnipper LE. Phase I trial of an interleukin-2 fusion toxin (DAB486IL-2) in hematologic malignancies: complete response in a patient with Hodgkin's disease refractory to chemotherapy. Cancer 1994; 73:1276-85. PubMed
  • Antman K, Ayash L, Elias A, Wheeler C, Schwartz G, Mazanet R, Tepler I, Schnipper LE, Frei E. High-dose cyclophosphamide, thiotepa, and carboplatin with autologous marrow support in women with measurable advanced breast cancer responding to standard-dose therapy: analysis by age. J Natl Cancer Inst Monogr 1994. PubMed